Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed primary cutaneous or unknown primary melanoma, including 1 of the following stages:~  * Stage IIIB or IIIC disease~    * Unresected, in-transit lymph node metastases (N2c or N3)~ * Stage IV disease~    * Distant skin, subcutaneous, lymph node, or pulmonary metastases (M1a or M1b)~      * No cerebral, bone, or other visceral metastases~* At least 1 measurable or evaluable lesion~  * Small-volume multiple cutaneous deposits allowed~* Progressive disease, as defined by 1 of the following criteria:~  * At least 20% increase in size in ≥ 1 measurable or evaluable lesion~ * Appearance of ≥ 1 new lesion since or during last treatment (if applicable) AND within the past 3 months~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-1~Life expectancy~* At least 6 months~Hematopoietic~* WBC ≥ 3,000/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 10.0 g/dL (transfusion allowed)~Hepatic~* SGOT and SGPT ≤ 2.5 times upper limit of normal (ULN)~* Lactic dehydrogenase normal~* No active hepatitis B or C infection~Renal~* Creatinine ≤ 1.5 times ULN~Immunologic~* No history of autoimmune disease~  * Vitiligo allowed~* No history of immunodeficiency syndrome~* No active bacterial, viral, or fungal infection within the past 72 hours~* HIV-1 or -2 negative~* Human T-cell lymphotrophic virus-I or -II negative~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* No contraindication to apheresis~* No other significant medical or surgical condition that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior vaccine therapy with ≥ 1 melanoma antigen or peptide~* More than 4 weeks since prior biologic therapy~Chemotherapy~* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)~Endocrine therapy~* No concurrent chronic systemic corticosteroids~Radiotherapy~* More than 4 weeks since prior radiotherapy~Surgery~* Not specified~Other~* More than 4 weeks since prior investigational products~* More than 4 weeks since prior chronic systemic immunosuppressive treatment~* No concurrent medication or treatment regimen that would prelude study participation~* No other concurrent anticancer treatment~* No other concurrent immunosuppressive treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).